|[May 23, 2014]
The International Myeloma Foundation Says Virotherapy Approach to Myeloma Could Lead to New Treatment Options
NORTH HOLLYWOOD, Calif. --(Business Wire)--
The International Myeloma Foundation (IMF) - improving the quality of
life of myeloma patients while working toward prevention and a cure -
says a new approach to myeloma treatment reported last week by Dr.
Stephen Russell and Dr. Angela Dispenzieri at the Mayo Clinic, which
showed that a myeloma patient treated with a massive dose of engineered
measles virus experienced a remission, offers a new path forward in
Dr. Russell presented initial findings from this work at the IMF's
International Myeloma Working Group (IMWG) Summit in 2011, and is
scheduled to discuss these new findings at the 2014 IMWG Summit in
Milan, Italy in June. "The IMF expects results from expanded clinical
trials and research into additional viruses to offer more information
about the potential of this exciting new virotherapy approach for
myeloma treatment," said Dr. Brian G.M. Durie, IMF Chairman. "This
stunning result opens many possibilities for further trials."
The IMF, which reaches more than 350,000 members in 120 countries, is in
a unique position to monitor the pressing concerns of the myeloma
patient community. "Patients have been extremely excited by the news
surrounding the virotherapy success achieved at the Mayo Clinic," said
Susie Novis, IMF President.
Dr. Durie cautions that there are some caveats associated with the
study: Only one patient resonded with a remission, and only 50% of
patients are candidates for the engineered measles virus treatment as
the rest have antibodies that will fight off the virus.
However, "despite many challenges, there is considerable optimism that
virotherapy is a dramatic new way forward to treat myeloma using a
completely different approach," said Dr. Durie, who spoke with Dr.
Russell this week and commented in depth on the news in his weekly IMF
blog. "It may or may not ever be a 'one-shot cure' but maybe a
'one-two punch' in which follow-up radiation or other therapy can
provide a 'knock-out' blow."
The engineered measles virus is just one virotherapy approach, he noted.
"Other viruses have been discussed with potential advantages over the
engineered measles virus." In particular, he said, "the vesicular
stomatitis virus (VSV) has no systemic (whole body) antibody response,
and all patients can be expected to have zero antibodies. The VSV works
faster and is definitely more potent than the measles virus in
ABOUT THE INTERNATIONAL MYELOMA FOUNDATION
Celebrating its 23rd anniversary, the International Myeloma Foundation
reaches more than 350,000 members in 120 countries worldwide. A 501 (c)
3 non-profit organization dedicated to improving the quality of life of
myeloma patients and their families, the IMF focuses on four key areas:
research, education, support, and advocacy. To date, the IMF has
conducted more than 250 educational seminars worldwide, maintains a
world-renowned hotline, and established the International Myeloma
Working Group (IMWG), a collaborative research initiative focused on
improving myeloma treatment options for patients. The IMF can be reached
at (800) 452-CURE (2873). The global website is�www.myeloma.org.
Follow the IMF on�Twitter
[ InfoTech Spotlight's Homepage ]